Abstract: Pemphigus are intraepidermal autoimmune bullous dermatoses that occur with lesions on the skin and / or mucous membranes. The most frequent types are pemphigus vulgaris and pemphigus foliaceus (classic and endemic). This consensus aims to present a complete and updated review of the treatment of these two more frequent forms of pemphigus, based on the literature and the personal experience of the authors. In moderate and severe cases of pemphigus vulgaris and foliaceus, systemic corticosteroid therapy (prednisone or prednisolone) is the treatment of choice. Adjuvant drugs, usually immunosuppressive drugs (azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide) may be prescribed as corticosteroid sparers in refractory cases or with contraindications to corticosteroids to minimize side effects. In severe and nonresponsive cases, corticosteroids in the form of intravenous pulse therapy, immunoglobulin and plasmapheresis / immunoadsorption can be administered. Immunobiological drugs, particularly rituximab, appear as a promising alternative. For milder cases, smaller doses of oral corticosteroid, dapsone and topical corticosteroids are options. At the end flowcharts are presented as suggestions for a therapeutic approach for patients with pemphigus vulgaris and pemphigus foliaceus.
INTRODUCTION
Pemphigus is a group of rare autoimmune bullous diseases that affect the skin and mucous membranes. Its estimated incidence in central Europe is 2 new cases/million inhabitants/year.
They undergo a chronic evolution, with significant morbidity and mortality, and significantly impair quality of life. 1, 2 They result from the production of pathogenic autoantibodies (usually IgG) that are directed against various desmosomal proteins (the desmogleins Dsg3 and Dsg1). The binding of these autoantibodies to desmosomal components compromises intraepidermal adhesion, leading to acantholysis and the formation of vesicles, blisters, and erosions on the skin and mucous membranes. [3] [4] [5] Various subtypes of pemphigus have been identified, based on their clinical and histopathological characteristics and the specific antigens against which autoantibodies are produced. The main types are pemphigus vulgaris (PV) and pemphigus foliaceus, but in the past several decades, nonclassical forms of pemphigus have been described, including paraneoplastic pemphigus, pemphigus herpetiformis, and IgA pemphigus. 6 Regardless of subtype, the formation of autoantibodies against desmosomal components has long been considered the chief event in the pathogenesis of pemphigus. In addition to the involvement of humoral immunity, the function of cellular immunity in it has been highlighted.
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EPIDEMIOLOGY
PV is the main clinical form of pemphigus, accounting for 70% of cases. 6 It is a rare disease, with an annual incidence that varies between 0.76 (Finland) and 16.1 (Israel) cases/million inhabitants, depending on the study population. Although it is universally occurring, PV primarily affects adults, peaking in incidence between the fourth and sixth decades of life. In Brazil, it also develops in young adults. Most studies have noted a higher incidence in women, with the female:male ratio ranging from 1.1 (Finland) to 5.0 (US). PV is considered the most severe form of pemphigus. 8, 9 
ETIOPATHOGENESIS
The etiology of PV is unknown. Possible triggering factors include environmental agents, infections, drugs, and tumors. It is linked to specific HLAs, such as HLA-DRB1*04:02 (Jewish) and HLADQB1*05:03. 10 PV is characterized by acantholysis and the formation of intraepidermal blisters, resulting from the presence of IgG autoantibodies against the transmembrane desmosomal glycoprotein Dsg3 (130 kD) and, in certain cases, Dsg1 (160 kD).
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CLINICAL CONDITION
The condition generally begins with mucous lesions that, after several weeks or months, start to affect the skin. Among mucous membranes, the most frequently involved is the oral mucosa, in 70% of cases, followed by the genital in 20%. Oral lesions are painful ulcers or eroded lesions that form in any area in the oral cavity, usually accompanied by dysphagia and weight loss. Other mucous membranes can be affected, such as the conjunctiva, pharynx, larynx, esophagus, and anal mucosa.
Vesicles and flaccid blisters develop on the skin, throughout the integument, predominating on the scalp, face, and upper chest.
These lesions rupture, giving rise to considerable areas of erosion that are painful. If the lesions are extensive, there might be disruptions in hydroelectrolyte balance, protein loss, and anemia. In addition, rupture of the cutaneous-mucosal barrier facilitates secondary infections. Pemphigus vegetans is a rare clinical subtype of PV that is characterized by vegetant cutaneous lesions in folds of the armpits, groin, and inframammary region. 6, 9, 12, 13 The main clinical differential diagnoses in PV are bullous pemphigoid, paraneoplastic pemphigus, and Stevens-Johnson syndrome. PV should be confirmed by histopathological examination of the skin and mucosal lesions with immunofluorescence techniques.
LABORATORY DIAGNOSIS
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Histopathological examination: Whenever possible, an entire vesicle should be removed by skin biopsy. PV shows low suprabasal intraepidermal cleavage with acantholytic (rounded) cells. These cells can also be viewed, isolated or in groups, from blisters or erosion smears by Tzanck test. Acantholysis is also present in hair follicles and sebaceous gland ducts. In vegetans pemphigus, there is also papillomatosis, in addition to neutrophil and eosinophil infiltrates.
Direct immunofluorescence:
IgG and C3 autoantibodies can be detected in a perilesional skin fragment (lacy pattern in the stratum spinosum).
Indirect immunofluorescence: Autoantibodies can be detected and titrated in serum in 80% to 90% of patients. Usually, the serum titer of autoantibodies correlates with the clinical activity of the PV.
TREATMENT
The treatment of autoimmune bullous dermatoses, including PV is usually based on systemic medications, because they comprise a severe group of mucosal and cutaneous diseases with significant morbidity and mortality. Treatment should be started as early as possible, and its goal is to achieve and maintain disease remission. Thus, the treatment is often prolonged and can last many years (average 5 to 10 years (should be repeated after 6 months and then annually).
Ophthalmological evaluation:
Initial and then annually.
Systemic treatment Corticosteroids
Systemic corticosteroids are the basis of the treatment for PV. They have potent anti-inflammatory and immunosuppressive activities. The introduction of these drugs in the 1950s was followed by a reduction in mortality from 75% to 30%. [15] [16] [17] -Oral administration: Prednisone is the most commonly used oral corticosteroid, followed by prednisolone and deflazacort. Although several groups prefer to administer a dosage of 40 to 60mg/day (prednisone) for patients with mild PV and 60 to 100mg/day for more severe conditions, most supply a full dose (1 to 2mg/kg/day po) for all patients from the outset, avoiding a progressive increase in dose. However, extremely high dosages, as used previously (3 to 4mg/kg/day), have been shown to be disadvantageous due to their frequent and severe side effects.
Corticosteroids act rapidly in PV, effecting improvement in several days and impeding the emergence of new lesions after 2 to 3 weeks. Complete re-epithelization can take up to 2 months. After the condition is controlled, defined as the disruption of the emergence of new lesions and total re-epithelialization of existing lesions, the corticosteroid dose is slowly reduced. The rate of this decrease should decline toward the end, which can sometimes take years, due to the lack of uniform protocols for this practice. Certain groups recommend that starting from a specific daily dose (usually 40mg/day prednisone), the drug should be administered every other day, which would minimize the side effects. Similarly, there is no consensus on how to increase the dose in cases of recurrence. Generally, relapse is milder than the initial presentation of the disease and requires doses of prednisone that are equal to or lower than the initial dose for control. 18, 19 -Pulse therapy: Corticosteroids can also be administered as pulse therapy for cases in which control with prednisone at dosages of over 1mg/kg/day is not achieved. To this end, methylprednisolone 1g/day IV and dexamethasone 300mg/day IV are used, both for 3 consecutive days. The advantage of pulse therapy is that it allows for a faster reduction in the prednisone dose, minimizing its side effects. 20, 21 Although corticosteroids are effective in controlling PV in most patients, they have frequent and potentially severe side effects, the most significant of which are hypertension, diabetes mellitus, cutaneous and systemic infections, gastric ulcer, osteoporosis, femoral head necrosis, glaucoma, and cortisone cataract. These side effects are partly responsible for the morbidity and lethality of the disease, often due to the increase in the frequency of consultations, laboratory tests, and hospital admissions. All patients should receive gastric mucosal protectors and vitamin D supplementation. 22 To minimize the side effects, morbidity, and mortality of PV, contrary to what was advocated several decades ago, it is recommended that the daily dosage of prednisone does not exceed 1.5mg/kg/ day-above this value, the likelihood of skin infection and evolution to septicemia (the main death cause in these patients) increases progressively. Thus, other drugs are recommended, in association with corticosteroids-termed adjuvant drugs (corticosteroid-sparing agents).
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Adjuvant drugs
When the condition is not controlled solely with corticosteroids or when the patient has clinical contraindications to high-dose corticosteroids (e.g., hypertension, diabetes mellitus, glaucoma, osteoporosis-all of which are frequent in the age group in which the prevalence of PV peaks), other drugs, called adjuvants or corticosteroid-sparing agents, should be incorporated. Adjuvant drugs also prevent relapses in previously controlled patients. The efficacy of AZA as a corticosteroid-sparing agent in autoimmune bullous diseases, particularly in PV, is well documented and is the oldest and most prescribed immunosuppressive medication in this context. 19, 26, 27 The recommended dosage of AZA in PV is 100 to 200mg/ day (1 to 3mg/kg/day), orally, divided into 2 doses. Its therapeutic effect begins after 4 to 6 weeks, which restricts its use as monotherapy. Three months of use should elapse before replacing it with another adjuvant when there is no satisfactory clinical response. 18, 28 Its main side effects are leukopenia, thrombocytopenia, anemia, pancytopenia, and hepatotoxicity. Long-term immunosuppression can increase the risk of infections and neoplasms. Individuals with a genetic deficiency in thiopurine methyltransferase (TPMT) present with greater sensitivity to AZA-induced myelotoxicity. This medication is contraindicated in pregnant women and nursing mothers.
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Mycophenolate mofetil (MMF)
After oral administration, MMF is absorbed and converted into its active metabolite, mycophenolic acid. This, in turn, selectively inhibits inosine monophosphate dehydrogenase, impeding purine synthesis in B and T cells and thus slowing their proliferation. 29 MMF has been used as an adjuvant to corticosteroids in patients with PV as first-line treatment and in non-responders to AZA.
Several groups prefer MMF to AZA as the first-line adjuvant therapy in PV, due to its lower hepatotoxicity and comparable efficacy.
Compared with AZA, MMF is a poorer corticosteroid-sparing agent but is more effective in controlling PV. 18, [30] [31] [32] The recommended dosage of MMF in PV is 2-3g/day, divided into 2 doses. Its main side effects are altered bowel habits, neutropenia, lymphopenia, and myalgia. Therapeutic failure should be considered only after 3 months of use at a dosage of 3g/day. 30, 33 An Bras Dermatol. 2019;94(2 Suppl 1):S20-32.
Rituximab
Chimeric anti-CD20 monoclonal antibody (which depletes normal and pathogenic B lymphocytes) has been used for cases of severe and refractory PV since 2006. 34 Following the administration of rituximab, there is a rapid and sustained depletion of circulating and tissue B lymphocytes that persists for at least 6 to 12 months.
Recent evidence demonstrates that it also affects T lymphocytes. 35 In June 2018, the US FDA approved rituximab for PV.
There are many prospective and retrospective studies that have proven its efficacy, leading to complete and sustained remission in most patients in 3 to 4 months. 34, [36] [37] [38] [39] A recent systematic review that included 114 studies and 1085 patients concluded that rituximab is an excellent treatment for refractory cases. 40 Rituximab should be administered IV as a slow infusion (4 to 6 hours). There are no standardized protocols for the use of rituximab in autoimmune bullous diseases, but studies have been published using the lymphoma protocol (375mg/m 2 , 1x/week for 4 weeks) and that for rheumatoid arthritis (1000mg with an interval of 2 weeks; can be repeated after 6 months). 36, [41] [42] [43] There seems to be no difference in percentage in remission or disease-free interval between these protocols. Rituximab can be used alone or in combination with IVIG, plasmapheresis, or immunoadsorption (the latter appears to prolong the response time with respect to rituximab alone). It can also be administered to patients who are already taking prednisone and immunosuppressants, and the dose reduction and suspension of the latter should be accelerated due to the increased risk of infection. 40, [44] [45] [46] [47] [48] 34 Rituximab is generally well tolerated, and serious adverse effects are rare. Infusion reactions (which can be reduced with prior administration of analgesics, antihistamines, and corticosteroids) include anaphylaxis, fever, hypotension, chills, headache, nausea, pruritus, and skin rash. In addition, neutropenia, hypogammaglobulinemia, and infections, including sepsis, are rarely reported. Certain authors and expert groups recomend rituximab as a first-line treatment option for PV.
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Cyclophosphamide
Cyclophosphamide is an alkylating agent that selectively affects B lymphocytes and antibody production. It can be administered orally in PV (1 to 3mg/kg/day) or intravenously, with or without dexamethasone IV, in the form of pulse therapy. 16 In such cases, dexamethasone is administered at 100mg/day IV for 3 days, with cyclophosphamide 500mg/day IV being administered on the first day. This pulse therapy is repeated every 2 to 4 weeks, between which an oral dose of cyclophosphamide 50mg/day and prednisone 1mg/kg/day is maintained. Treatment failure should be considered after 3 months of use at 2mg/kg/day. 19, 36, 53 Its main toxic effects are infertility, predisposition to neoplasia, lymphopenia, and sepsis. Due to its greater toxicity, it can be considered as an adjuvant only in cases that are refractory to AZA and MMF. Medication doses should be maintained until the condition is controlled, defined as re-epithelization of approximately 80% of skin and mucosal lesions and no emergence of new lesions for at least 2 weeks. Oral mucosal lesions usually resolve more slowly than skin lesions. At this stage, the corticosteroid dose can be reduced slowly.
Maintenance of remission
The dose of the medication should be decreased gradually to minimize side effects. The ultimate goal is to keep the disease controlled with a dose of prednisone of up to 10mg/day. PV is a 
Treatment suspension
Complete remission can occur, having been observed in 38%, 50%, and 75% of patients after 3, 5, and 10 years after diagnosis, respectively. Another study found that 59% of patients were without treatment after 3 years. However, premature withdrawal should be avoided, being rarely possible before 1 year.
We present an algorithm for the treatment of pemphigus vulgaris ( Figure 1 ).
EVOLUTION AND PROGNOSIS
Before the advent of corticosteroids and immunosuppressants, PV had a 2-year mortality rate of 50%. Since then, the mortality rate has dropped to approximately 10%. The main cause of death in patients with PV is septicemia. Patients often present as people with large burns, experiencing loss of the skin-mucosal barrier, which promotes infections and hydroelectrolytic and metabolic disorders. Oral lesions are usually more resistant to treatment and can persist for years, significant impairing patients' quality of life.
Generally, it is possible to obtain total disease control, which allows the medication to be suspended, but the patient should be kept under observation, because relapses are frequent. 8, 10, 12, 28 CONCLUSIONS PV is a rare disease. It is difficult to compare published studies among adjuvant drugs in terms of their efficacy in the control of PV, prevention of relapse, side effects, morbidity, and mortality, due to differences in study design, study populations, and the doses and combinations of the drugs. Primarily, this obstacle is attributed to the lack of randomized controlled clinical trials.
Recent systematic reviews and meta-analyses have concluded that systemic corticosteroids (prednisone or prednisolone) should form the basis of PV treatment but have not generated a consensus on the best initial corticosteroid dose or adjuvant drug. 24 
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Drugs -Thiol drugs can induce PF and, less frequently, PV, of which penicillamine and captopril are the most common. Other drugs include penicillins, cephalosporins, enalapril, rifampicin, and non-hormonal anti-inflammatory drugs.
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Genetic -FS can occur in genetically related relatives (~20%) and is associated with the expression of certain DRB1 alleles (*0404, *1402, *1406) of the type II major histocompatibility complex.
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Autoantigen -Desmoglein-1 is a 160-kD transmembrane glycoprotein of the cadherin family (calcium-dependent cell adhesion molecules) in desmosomes and has 5 ectodomains, EC1-5. Based on the desmoglein compensation theory, Dsg-1 expression is more intense in the upper portions of the epidermis, whereas in PV, Dsg-3 predominates in the lower layers of the epidermis and in mucous membranes.
9,95-102
Autoantibodies -Autoantibodies that trigger the disease belong to the IgG4 subclass. Normal controls in endemic areas have low levels of IgG1 and IgG4, but in FS patients, the IgG1 levels are the same but IgG4 is significantly elevated by up to 19-fold. IgG4 is pathogenic in the mouse model of FS. In the preclinical phase, IgG1 autoantibodies are directed against the EC5 ectodomains of Dsg-1, and in the disease phase, IgG4 autoantibodies react against EC1-2-a phenomenon that is known as epitope spreading. 9, 82, 87, [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] 4 Interleukins -Many proinflammatory and anti-inflammatory chemokines and cytokines are produced in the immune response in PF. Although their function in the disease and its pathophysiology remains unknown, they tend to generate a Th2 response, with increased levels of IL-6, TNF-α, and IL-22.
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CLINICAL CONDITION
The clinical manifestations of FS, classical Cazenave PF, and drug-induced pemphigus are similar. 
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Neonatal pemphigus foliaceus is rarer than neonatal PV, due to the predominance of Dsg-3 compared with Dsg-1 in the newborn's skin. Mothers of these newborns usually have disseminated disease and high titers of anti-Dsg1 autoantibodies. [121] [122] [123] [124] In the differential diagnosis, seborrheic dermatitis, impetigo, chronic cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, IgA pemphigus, and the pemphigus variant of non-IgA subcorneal pustular dermatosis should be considered. In the evaluation of patients with erythroderma that is to be clarified, immunological examinations are recommended to rule out PF. 78, 9, 81 
LABORATORY DIAGNOSIS
To confirm the diagnosis of any autoimmune bullous disease, clinical, histopathological, and immunological criteria are required. 9, 89, [125] [126] [127] Histopathology -In PF, cleavage below the stratum corneum is observed with the presence of acantholytic keratinocytes in or adjacent to the granulosa layer, and occasional neutrophils are seen. In the dermis, a mixed inflammatory infiltrate is observed with eosinophils and neutrophils; eosinophils are more prevalent in drug-induced PF. A biopsy for histopathology should be performed at the vesicle/blister or recent erosion edge, with a 4-mm punch. it is suggested that the clinical condition be evaluated using the Karnofsky index-a 100% value refers to a normal person, with no evidence of disease; hospitalization is indicated when this index is 50% or less (50% refers to a patient requiring considerable help, often medical and/or specialized care, and 40% refers to a disabled patient who requires special and comprehensive care).
Direct immunofluorescence (DIF)
In deciding which regimen to prescribe for a patient with FS, the extent of pemphigus should be determined. A practical method would be to consider up to 1% involvement as a mild clinical form, up to 10% as moderate, and over 10% of compromised body area (FS active lesions) as severe, with 1% representing the sum of the area of FS lesions, corresponding approximately to the hand palmar area. In some departments, a protocol is included to verify extent and severity of the lesions using the PAAS (Pemphigus Area and Activity Score) and ABSIS (Autoimmune Bullous Skin Disorder Intensity Score) scores. 135, 136 Prior to initiation of therapy, complete blood count, creatinine, sodium, potassium, transaminases, gamma-glutamyl transferase (gGT), alkaline phosphatase, total proteins and protein fractions, fasting glycemia, serology for hepatitis B and C and human immunodeficiency virus (HIV), and chest x-ray should be exami- Methotrexate is an interesting option, based on its low cost and wide availability. However, it is hepatotoxic. It is used at 7.5 to 25mg/week, administered over 1 or 2 consecutive days. After 24 hours, folic acid should be prescribed at a dose of 5mg. Alcohol, sulfamidic derivatives, and allopurinol are banned.
For less extensive forms, one can attempt dapsone 100mg/d or up to 1.5mg/kg/d, because it has also corticosteroid-sparing effects. However, glucose-6-phosphate dehydrogenase (G6PD) activity should be evaluated beforehand. Considering that pemphigus is an antibody-mediated disease, dapsone use is controversial.
Cyclophosphamide can also be used at 500mg IV as a bolus or 2mg/kg/d. It has corticosteroid-sparing effects, but the risk of sterility, hemorrhagic cystitis, and secondary malignant neoplasia should be considered.
The evidence indicates that the major benefit of adjuvant use is the corticoid-sparing effect-not in modifying the course of the disease. In addition, adjuvants reduce the risk of relapse without altering remission rates.
Newer and more relevant therapies
Rituximab (monoclonal anti-CD20) is indicated when the patient is refractory to conventional therapy or if prednisone is re- We present an algorithm for the treatment of fogo selvagem (see Figure 2) Maintenance after consolidation phase: CE should be reduced progressively, after disease control or the end of the conso- Treatment discontinuation: Discontinuation is based primarily on clinical signs and may be accompanied by anti-Dsg ELISA and IIF. In some centers, negativity by IIF is recommended. Discontinue CS in patients with complete remission and minimal therapy, and discontinue adjuvants 6 to 12 months later.
EVOLUTION AND PROGNOSIS
Until the 1950s, the prognosis was poor, with a significant mortality rate due to cachexia and systemic infection. With the introduction of systemic corticosteroid therapy, this rate fell to 30%.
By combining it with immunosuppressive adjuvants and recognizing and treating the adverse effects of systemic corticosteroids, the mortality rate was reduced to approximately 6%. PF without compromising mucous membranes has a better prognosis than pemphigus vulgaris. PF usually has a chronic evolution and it is necessary increase the posology of the medication when relapses 
